A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 19 Jan 2015
Price : $35 *
At a glance
- Drugs Encenicline (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Pharmacokinetics
- Sponsors FORUM Pharmaceuticals
- 14 Jan 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.
- 22 Nov 2013 New trial record